Objectives: Determine the effect of propofol anesthesia on regional rates of cerebral protein synthesis (rCPS) and leucine kinetics in adult males with the L-[1-11 C]leucine PET method (Schmidt et al, JCBFM 2005; 25:617-28; Smith et al, JCBFM 2005;25:629-40; Bishu et al, JCBFM 2008;28:1502-13). Methods: Subjects (20-24 years; n = 10) were dynamically scanned on the High Resolution Research Tomograph for 90 mins following 11 C-leucine injection. Region of interest-based analyses were used to estimate kinetic model rate constants. rCPS, l (fraction of unlabeled leucine in the tissue precursor pool for protein synthesis derived from arterial plasma), and C E (concentration of unlabeled leucine in tissue precursor pool) were calculated. Sedation was monitored with the bi-spectral index (BIS) monitor (Gan et al, Anesth 1997;87:808-15). Results: Mean ( ± s.d.) plasma leucine concentrations were similar in awake (118 ± 14 nmol/mL) and propofol-anesthetized (109±21) states at baseline as were physiological variables. Clearance curves of arterial plasma 11 C-leucine were also similar in both states. Tissue 11 C-leucine clearance was slower in the propofol-anesthetized state in 6/8 cortical and 2/6 subcortical regions examined, indicating an increased half-life of unlabeled leucine in tissue. Estimated C E was 30% higher in most cortical (7/8) and subcortical (4/6) regions. Under propofol anesthesia, l tended to be slightly higher (NS); rCPS was unchanged (Table) . In both awake and anesthetized conditions, rCPS varied regionally, whereas l was more uniform. The mean BIS score was 34, consistent with anesthesia. Conclusions: Since leucine participates in glutamate trafficking and leucine metabolites are oxidized via the TCA cycle, the longer half-life of unlabeled leucine in tissue is consistent with the effect of anesthetics to decrease neuronal activity and the rate of cerebral energy metabolism. Despite these changes in kinetics, rCPS remained unaffected.
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Supported by IRP/NIMH; CC, NIH. Objectives: 5-HT 4 receptors are of clinical relevance due to their involvement in memory and learning and their presumed ability to reduce the pathological accumulation of cerebral b-amyloid in Alzheimer's disease (AD). The aim of this study was to investigate the effects of age and gender on 5-HT 4 receptor binding in both the high-binding region striatum, the global neocortex, and 3 cortical regions of importance for memory, learning and AD. Methods: A bolus injection of [ 11 C]SB207145 was followed by a 2-h dynamic PET scan in a GE Advance scanner in 30 healthy volunteers (16 men, mean age 44.4 years range 19.9 to 86.2). Volumes of interest (VOIs) were delineated automatically on co-registered 3T MRIs. Partial volume (PV) corrected timeactivity curves were extracted from the VOIs, including gray matter voxels only, and BP ND was modeled with SRTM. BP ND in 5 VOIs were investigated for gender differences and correlation to age. Results: Although non PV corrected BP ND correlated negatively with age in some regions, when correcting for atrophy, we found positive correlations in the high-binding region striatum (R = 0.3818, P = 0.0373), in the dorsolateral prefrontal cortex (R = 0.42, P = 0.0208, see Figure) , and a tendency was found in the posterior cingulate gyrus (R = 0.3378, P = 0.0679). No correlations were found in the global neocortex or in the hippocampus. Using age as a covariate, gender differences in PV corrected BP ND were only found in the striatum, where a tendency for 6.8% higher BP ND in women was found (P = 0.068). In a post hoc analysis, this difference was driven by putamen, which was 8.3% higher in women (P = 0.0355). Conclusions: To our knowledge, this is the first time an increase of 5-HT receptors with age has been found. The up-regulation of 5-HT 4 receptors with age could be a compensation for a lower serotonergic tone with age. It is highly interesting that the cortical increase with age is seen in the regions affected by the highest b-amyloid accumulation in studies with 11 C-PIB PET in AD.
A localized gender difference of 8.3% is somewhat surprising, as most receptors do not show gender differences. However, depression and anxiety are more prevalent in females. the striatum. Using PET radiotracers for a4b2 nAChR ( 18 F-nifene) and dopamine D2/D3 receptors ( 18 F-fally pride (FP) and 18 F-desmethoxyfallypride (DMFP)) we have evaluated acute effects of nicotine in rodents using MicroPET on the two receptor systems. Methods: Imaging was done using an Inveon Micro-PET scanner. 18 F-Nifene, 18 F-FP and 18 F-DMFP were synthesized as previously reported. Sprague Dawley rats (400 to 600 g) anesthetized with isoflurane were used for PET studies. Radiotracers (0.8 to 1 mCi) were given iv. Test-retest was carried out to evaluate reproducibility. Rats were imaged for 90 mins (for 18 F-nifene and 18 F-DMFP) and 150 mins (for 18 F-FP) and binding potential (BP ND ) were measured. Post-18 F-nifene nicotine challenge (0.3 mg/kg, free base) was used to measure reversibility and nicotine occupancy was measured using various doses (0.02 to 0.50 mg/kg) injected 15 mins before 18 F-nifene. Nicotine (0.3 mg/kg) was coinjected with 18 F-FP and 18 F-DMFP to measure potential dopaminergic effects. Data was analyzed using ASIPRO and PMOD. For ex vivo studies, animals were sacrificed for autoradiographic analysis of brain sections using Optiquant imaging system. Results: 18 F-Nifene binding to thalamic and other brain regions was consistent with the a4b2 nAChR distribution. Test-retest values for the thalamus varied less than 5% (BP ND = 1.30, n = 3 rats, using reference cerebellum (CB)), confirming reliability of 18 F-nifene binding. Post-injection of nicotine (0.3 mg/kg, + 30 mins) rapidly displaced specifically bound 18 F-nifene indicating > 90% occupancy. Low dose nicotine (0.02 mg) reached about 50% occupancy. 18 F-FP binding to D2/D3 receptors gave BP ND values of dorsal striata (DST) = 15; ventral striata (VST) = 11; and with nicotine values were 20 and 12.5, respectively. 18 F-DMFP binding to D2/D3 receptors in striata (ST) gave BP ND of 1.8 (without nicotine) and 2.9 (with nicotine). Ex vivo studies revealed similar effects in the case of 18 F-FP, while 18 F-DMFP binding exhibited E20% reduction (0.5 mg/kg nicotine) in VST when internal capsule as reference. Conclusions: Nicotine dose-dependently occupies a4b2 nAChR and saturates receptors at 0.3 mg/kg. Although little or no effect on cerebral blood volume or flow to the ST by nicotine has been reported 1,3 delivery of dopamine D2/D3 receptor tracers, 18 F-FP and 18 F-DMFP to ST was significantly increased, with a net increase in measured BP ND . Nicotine has been shown to marginally increase dopamine levels in the nucleus accumbens and other brain regions 2 and therefore the increase in delivery and BP ND is unlikely due to greater D2/D3 receptor availability. Recently, 18 F-FP has been used in heavy smokers and a small decrease in D2/D3 receptor availability was observed in the putamen. Further analyses are underway to delineate the effect of nicotine on 18 F-FP and 18 F-DMFP.
Acute nicotine effects on the distribution of nicotine
Research Supported by NIH R01 AG029479 and R01EB006110.
Background and aims: Phosphodiesterase-4 (PDE4), a major phosphodiesterase isozyme hydrolyzing the second messenger cAMP, may play a pivotal role in brain diseases and the effects of centrally acting drug. Rolipram is a selective inhibitor of PDE4 and the binding study using [ 11 C]rolipram with PET should allow the function of the cAMP second messenger cascade to be explored. cAMP Dependent protein kinase (PKA) has been reported to phosphorylate PDE4 and affect the enzyme activity. We recently found that both in vivo B max and K D values of [ 11 C](/iSR//iS)-rolipram were significantly greater in conscious rats than in anesthetized rats. In the present PET study, we examined effects of PKA modulators on the binding of [ 11 C](/iSR//iS)rolipram and [ 11 C](/iSS//iS)-rolipram (affinity of (/iSS) is 1/20 of that of (/iSR)) using conscious rats. Methods: For PET scans using conscious rats (n = 26), an acrylic plate was permanently attached to the skull. The animals were trained to acclimate to the scanning holder for at least ten days before the PET experiment. On the day of PET scan, 10 nmol of db-cAMP (cAMP analogue and PKA activator) or 100 nmol of Rp-cAMPS (PKA inhibitor) was injected into the left striatum using 30-gauge needle three times before the scan. At the same time, saline was administered into the right striatum. The animals were given an intravenous bolus injection Results: When using [ 11 C](/iSR//iS)-rolipram, db-cAMP significantly increased the AUC in left striatum (P < 0.002). In contrast, a significant decrease of AUC was found by pretreatment of Rp-cAMPS (P < 0.002). On the other hand, these effects of neither of these PKA modulators were not observed in [ 11 C] (/iSS//iS)-rolipram PET experiments. Conclusions: Significant increase and decrease of [ 11 C](/iSR//iS)-rolipram binding were observed by PKA activator and inhibitor, respectively. These effects were not caused by changes in brain regional blood flow, since there were no effects when [ 11 C] (/iSS//iS)-rolipram was used. These results support the value of measuring [ 11 C]rolipram binding in brain for assessing responses to physiological or pharmacological challenges to the cAMP second messenger system. 335. Regional differences in P-Glycoprotein function at the human blood-brain barrier Background and aims: P-glycoprotein (P-gp) acts at the blood-brain barrier (BBB) as an active cell membrane efflux pump for several endogenous and exogenous compounds. Recent animal data suggest regional differences of cerebral P-gp activity. 1 PET with the P-gp substrate (R)-[ 11 C]verapamil (VPM) can be used to measure cerebral P-gp function, but low brain uptake of VPM hampers the mapping of regional differences in P-gp function. This limitation can be overcome by P-gp modulation with moderate doses of P-gp inhibitors. The aim of this study was to assess regional P-gp function in humans before and after administration of the third-generation P-gp inhibitor tariquidar (TQD). Methods: 5 healthy volunteers underwent paired VPM PET scans and arterial blood sampling, before and at 3 h after i.v. administration of TQD (2 mg/kg body weight). VPM distribution volumes (DV) before and after TQD administration were calculated using a 4-rate-constant-2-tissue-compartment model. Parametric images depicting distribution volume (DV) differences between the 2 PET scans were generated using the pixel-wise Logan plot and analyzed by statistical parametric mapping (SPM5). TQD concentrations in venous plasma were quantified using liquid chromatography/mass spectrometry. Purpose: The purpose of this study was to investigate P-glycoprotein function at the human blood-brain barrier in vivo. Results: TQD administration resulted in significant increases (paired t-test) in whole-brain grey matter DVs and influx rate constants (K 1 ) of VPM across the BBB (DV = 0.64 ± 0.12 and 0.79 ± 0.07, P = 0.012; K 1 = 0.034±0.01 and 0.049±0.01, P = 0.024, before and after TQD, respectively). A strong correlation was observed between TQD exposure in plasma and change in brain DV after administration of TQD (r = 0.932, P = 0.021). SPM analysis revealed significantly smaller DV increases in cerebellum, hippocampus, parahippocampus, enthorinal cortex, inferior temporal lobe, brain stem and cerebellum as compared to other brain regions, which points to increased P-gp expression and function in these regions. Conclusion: TQD significantly increased brain distribution of VPM, due to increased influx. Regional differences in VPM DV changes in response to TQD treatment suggest regional variability of cerebral P-gp function, which might make some brain areas more resistant and others more vulnerable to the accumulation of P-gp substrates.
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